Stock market analyst Sudarshan Sukhani has maintained 'buy' rating on Dr Reddy's Laboratories Ltd stock with short term target of Rs 1500.

According to analyst, the investors can buy the stock stop loss of Rs 1455.

Today, the stock of the company opened at Rs 1467.15 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 47.96 and 30.66 respectively.

The share price has seen a 52-week high of Rs 1515 and a low of Rs 750.50 on BSE.

Dr Reddys Laboratories, on June 29, introduced Anastrozole tabs (1mg) in the United States.

Anastrozole tabs, a generic edision of Arimidex, had twelve-monthly sales of $927 million in the US market.

Arimidex is available in 30 count bottles.

Dr. Reddy's is a vertically structured, international pharma company with established research abilities and presence across the pharma value chain.

The company makes active pharmaceutical ingredients (APIs) and finished dosage forms and sells them in the worldwide market, with a concentration on the US, Europe, India and Russia.

Besides, the drug discovery division of Dr Reddy's carries out basic research in the fields of diabetes, heart disease, inflammation and bacterial infection.